Antihistone antibodies in patients with localized scleroderma

Sato, Shinichi; Ihn, Hironobu; Soma, Yoshinao; Igarashi, Atsuyuki; Tamaki, Takeshi; Kikuchi, Kanako; Ishibashi, Yoshihiro; Takehara, Kazuhiko

doi:10.1002/art.1780360815

Cited by 106 publications

(107 citation statements)

References 15 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ELISA for anti-topo II␣ antibodies was performed as previously described (1). Briefly, 96-well plates were coated with purified human topo II␣ protein (1 g/ml; TopoGEN, Columbus, OH).…”

Section: Methodsmentioning

confidence: 99%

“…Autoimmune mechanisms are considered to play an important role in the induction of localized scleroderma since it, especially generalized morphea, is accompanied by various autoantibodies, such as antinuclear antibody, antihistone antibody, anti-singlestranded DNA (anti-ssDNA) antibody, rheumatoid factor, and lupus erythematosus cell phenomenon (1,2). However, autoantibodies to DNA topoisomerase I (topo I) and centromere, which are specific to SSc, are absent in localized scleroderma, with few exceptions (1).…”

mentioning

confidence: 99%

“…However, autoantibodies to DNA topoisomerase I (topo I) and centromere, which are specific to SSc, are absent in localized scleroderma, with few exceptions (1). Thus, although SSc and localized scleroderma share cutaneous fibrosis, specificities of autoimmunity associated with these diseases are distinct.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Anti‐DNA topoisomerase IIα autoantibodies in localized scleroderma

Hayakawa¹,

Hasegawa²,

Takehara³

et al. 2004

Arthritis & Rheumatism

Self Cite

View full text Add to dashboard Cite

Objective. To determine the prevalence and clinical correlation of anti-DNA topoisomerase II␣ (antitopo II␣) antibody in patients with localized scleroderma.Methods. Anti-topo II␣ antibodies or anti-DNA topoisomerase I (topo I) antibodies were determined by enzyme-linked immunosorbent assay (ELISA) and immunoblotting. Inhibition of topo II␣ enzymatic activity by the antibodies was evaluated by decatenation assays using kinetoplast DNA as a substrate. Results. IgG or IgM anti-topo II␣ antibody was detected in 76% ( Conclusion.The results of the present study indicate that anti-topo II␣ is a major autoantibody in localized scleroderma, and is distinct from anti-topo I antibody in SSc.

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Anti‐DNA topoisomerase IIα autoantibodies in localized scleroderma

Hayakawa¹,

Hasegawa²,

Takehara³

et al. 2004

Arthritis & Rheumatism

Self Cite

View full text Add to dashboard Cite

show abstract

“…Localized scleroderma, especially generalized morphea, has been reported to be accompanied by various immunologic abnormalities including anti-nuclear antibody, anti-single-stranded DNA (ssDNA) antibody, rheumatoid factor (RF), and lupus erythematosus cell phenomenon [2][3][4][5][6][7][8]. In our survey of anti-nuclear antibodies in sera of patients with localized scleroderma by indirect immunofluorescence, we noted that patients whose sera produced cytoplasmic staining constituted a characteristic subset, showing the distribution of elderly onset of the disease.…”

Section: Introductionmentioning

confidence: 99%

Autoantibodies to mitochondrial 2-oxo-acid dehydrogenase complexes in localized scleroderma

Fujimoto

Sato

Ihn

et al. 1996

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYSera from patients with localized scleroderma frequently produce cytoplasmic staining by indirect immunofluorescence, although the antigen remains to be determined. We studied the prevalence, antigen specificity and associated clinical characteristics of anti-cytoplasmic antibodies in localized scleroderma. Serum samples from 60 patients with localized scleroderma were examined by indirect immunofluorescence analysis and immunoblotting. By immunofluorescence analysis on HEp-2 cell substrate, seven of 60 (12%) patients were shown to be positive for anti-cytoplasmic antibodies. Among these, six patients with generalized morphea had anti-mitochondrial antibodies as shown by immunoblotting: they showed reactivity with the E2 component of pyruvate dehydrogenase complex (PDC), with protein X, and with the E2 component of ® -oxo-glutarate dehydrogenase complex, while two of them showed reactivity with PDC-E1®. One of these patients who was positive for anti-PDC-E1® antibody showed laboratory abnormalities, suggesting the presence of primary biliary cirrhosis. The age of disease onset was significantly higher in these six patients than in those without anti-mitochondrial antibodies. Furthermore, five of them were classified into generalized morphea with multiple plaque lesions but without linear lesions (multiple plaque type). These observations suggest that major antigens for anti-cytoplasmic antibodies in patients with localized scleroderma are mitochondrial enzymes, 2-oxo-acid dehydrogenase complexes. Patients with anti-mitochondrial antibodies may comprise a unique subset of localized scleroderma designated multiple plaque type of generalized morphea of older onset.

show abstract

“…Immunoblotting was performed using recombinant human caspase-3 (R&D Systems) as previously described [28]. Recombinant human caspase-3 (1µg/lane) was subjected to electrophoresis and electrotransferred to nitrocellulose sheets.…”

Section: Immunoblottingmentioning

confidence: 99%

Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis

et al. 2009

Self Cite

View full text Add to dashboard Cite

Objective: To determine the presence or levels of antibodies (Abs) against caspase-3 and their clinical relevance in systemic sclerosis (SSc).Methods: Anti-caspase-3 Ab was examined by enzyme-linked immunosorbent assay and immunoblotting.Results: IgG anti-caspase-3 Ab levels in SSc patients were higher than in normal controls.SSc patients positive for IgG anti-caspase-3 Ab had significantly longer disease duration, more frequent presence of decreased %VC and %DLco, and elevated levels of serum immunoglobulin and erythrocyte sedimentation rates. IgG anti-caspase-3 Ab levels correlated positively with serum IgG levels, renal vascular resistance, and serum levels of 8-isoprostane.Immunoblotting analysis confirmed the presence of anti-caspase-3 Ab in sera from SSc patients. Caspase-3 enzymatic activity was inhibited by IgG isolated from SSc sera containing IgG anti-caspase-3 Ab. Conclusion:These results suggest that autoantibody against caspase-3 is generated in SSc and that this Ab is related to the severity of pulmonary fibrosis, vascular damage, and inflammation.

show abstract

Antihistone antibodies in patients with localized scleroderma

Cited by 106 publications

References 15 publications

Anti‐DNA topoisomerase IIα autoantibodies in localized scleroderma

Anti‐DNA topoisomerase IIα autoantibodies in localized scleroderma

Autoantibodies to mitochondrial 2-oxo-acid dehydrogenase complexes in localized scleroderma

Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis

Contact Info

Product

Resources

About